Margins and market shares: Pharmacy incentives for generic substitution

European Economic Review

Volumn 61, Issue , 2013, Pages 116-131

  Brekke, Kurt Richard ^a   Holmås, Tor Helge ^b   Straume, Odd Rune ^c,d  

^a NORWEGIAN SCHOOL OF ECONOMICS   (Norway)

^b Uni Rokkan Centre   (Norway)

^c UNIVERSITY OF MINHO   (Portugal)

^d UNIVERSITY OF BERGEN   (Norway)

Author keywords

Generic substitution; Pharmaceuticals; Pharmacies

Indexed keywords

DATA SET; DRUG PRESCRIBING; INCENTIVE; MARKETING; PANEL DATA; PHARMACEUTICAL INDUSTRY;

EID: 84877074495     PISSN: 00142921     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.euroecorev.2013.02.005     Document Type: Article

References (22)

1. Aronsson T., Bergman M.A., Rudholm N. The impact of generic drug competition on brand name market shares-evidence from micro data. Review of Industrial Organization 2001, 19:425-435.
2. Baum, C.F., Schaffer, M.E., Stillman, S., 2007. Enhanced routines for instrumental variables/GMM estimation and testing. Boston College Economics Working Paper No. 667.
3. Bergman M.A., Rudholm N. The relative importance of actual and potential competition. empirical evidence from the pharmaceuticals market. Journal of Industrial Economics 2003, 51:455-467.
4. Bernheim B.D., Whinston M.D. Common marketing agency as a device for facilitating collusion. RAND Journal of Economics 1985, 16:269-282.
5. Bernheim B.D., Whinston M.D. Common agency. Econometrica 1986, 54:923-942.
6. Brekke K.R., Grasdal A.L., Holmås T.H. Regulation and pricing of pharmaceuticals. reference pricing or price cap regulation?. European Economic Review 2009, 53:170-185.
7. Brekke K.R., Holmås T.H., Straume O.R. Reference pricing, competition and pharmaceutical expenditures. theory and evidence from a natural experiment. Journal of Public Economics 2011, 95:624-638.
8. Coscelli A. The importance of doctors' and patients' preferences in the prescription decision. Journal of Industrial Economics 2000, 48:349-369.
9. European Generic Medicines Association, 2009. How to Increase Patient Access to Generic Medicines in European Healthcare systems. Brussels.
10. Frank R.G., Salkever D.S. Generic entry and the market for pharmaceuticals. Journal of Economics and Management Strategy 1997, 6:75-90.
11. Grabowski H.G., Vernon J. Brand loyalty, entry and price competition in pharmaceuticals after the 1984 Drug Act. Journal of Law and Economics 1992, 35:331-350.
12. Hellerstein J.K. The importance of the physician in the generic versus trade-name prescription decision. RAND Journal of Economics 1998, 29:108-136.
13. Iizuka T. Experts' agency problems. evidence from the prescription drug market in Japan. RAND Journal of Economics 2007, 38:844-862.
14. LMI, 2009. Fact and figures. The Association of the Pharmaceutical Industry in Norway, Oslo.
15. Liu Y.-M., Yang Y.-H., Hsieh C.-R. Financial incentives and physicians' prescription decisions on the choice between brand-name and generic drugs. evidence from Taiwan. Journal of Health Economics 2009, 28:341-349.
16. Lundin D. Moral hazard in physician prescription behavior. Journal of Health Economics 2000, 19:639-662.
17. Pavcnik N. Do pharmaceutical prices respond to potential patient out-of-pocket expenses?. RAND Journal of Economics 2002, 33:469-487.
18. Pharma Profile 2008-Pharmaceutical Industry 2008, Pharmaceutical Research and Manufacturers of America, Washington, DC.
19. Raskovich A. Retail buyer power through steering. Economics Letters 2007, 96:221-225.
20. Schaffer, M.E., 2007. xtivreg2: stata module to perform extended IV/2SLS, GMM and AC/HAC, LIML and k-class regression for panel data models.
21. Staiger D., Stock J.H. Instrumental variables regression with weak instruments. Econometrica 1997, 65:557-586.
22. Telser L.G. Why should manufacturers want fair trade?. Journal of Law and Economics 1960, 3:86-105.